Interim 24-Week Data from PhaseOut DMD

In January and February 2018, Summit reported interim data from PhaseOut DMD after patients were dosed with ezutromid for 24 weeks.  This page brings together the press releases, webcasts and other key opinion leaders calls that have taken place since the release of these data.

70th American Academy of Neurology Annual Meeting

Summit presented additional analysis from the interim 24-week data from PhaseOut DMD at the annual AAN meeting held in Los Angeles between April 21-27. A copy of the press release and presentation are available to view by clicking on the fSummit presented additional analysis from the interim 24-week data from PhaseOut DMD at the annual AAN meeting held in Los Angeles between April 21-27. A copy of the press release and presentation are available to view by clicking on the following links.

Summit Presents New 24-Week Analyses from PhaseOut DMD at AAN 2018 (issued 20 April 2018)

2018 AAN Presentation (PDF)

Duchenne Muscular Dystrophy image boy

Press releases

EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA (Released January 25, 2018)

SUMMIT ANNOUNCES NEW ANALYSIS SHOWING EZUTROMID SIGNIFICANTLY REDUCED MUSCLE INFLAMMATION IN PHASE 2 CLINICAL TRIAL IN DMD (Released February 26, 2018)

Investor Conference Calls

Interim Data Investor call (January 25, 2018)

Slingshot Insights Key Opinion Leader call (February 22, 2018, sponsored by Summit)

DMD Community Events

Community webinar (February 7, 2018)

Community FAQs (February 7, 2018)